Notable Buzzer: Endologix, Inc.’s (ELGX)
Endologix, Inc.’s (ELGX) , a stock from Medical Instruments & Supplies Industry, has a value of $6.74 per share, noted a price change of -0.44% in recent trade close. The price to sales ratio is 3.02. The lower price P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. A low P/S ratio may indicate possible undervaluation, while a ratio that is significantly above the average may suggest overvaluation. Abbreviated as the P/S ratio or PSR, this ratio is also known as a “sales multiple” or “revenue multiple.”
Annual earnings per share (EPS) growth noted at -40.80% in past 5 Years and Long-term annual earnings per share (EPS) growth is expected to reach 36.95% in coming 5 years. The company is estimating to achieve earnings per share (EPS) growth of -49.90% in this year and the earnings per share (EPS) growth expected to be 6.70% in the next year.
The stock has P/B of 4.16. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock’s market value to its book value. It is calculated by dividing the current closing price of the stock by the latest quarter’s book value per share. A lower P/B ratio could mean that the stock is undervalued. However, it could also mean that something is fundamentally wrong with the company. As with most ratios, be aware that this varies by industry. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately.
Analysts mean Recommendation on a stock is noted at 2.20. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.
The performance for week is -3.58% and the performance for quarter is at -31.85%. The performance for month is 6.14% and the performance for half year is -42.10%. Its monthly volatility value of 4.62% and volatility for the week is valued at 3.45%. The performance for Year to Date (YTD) is 17.83%.
The net percent change held by Institutional Investors has seen a change of -5.97% in last three month period. Insiders own 1.20% of Endologix, Inc.’s (ELGX) shares. During last six month record, the net percent change kept by insiders has observed a change of 4.67%.
Indicating how profitable this stock is relative to its assets, the ROA value is observed at -38.50%. The ROA tells us exactly what earnings were generated from the invested capital. A ROI of -16.10% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.
P/E Ratio is for valuing a company that measures its current share price relative to its per-share earnings. The price to earnings ratio indicates the expected price of a share based on its earnings. As a company’s earnings per share being to rise, so does their market value per share. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company’s shares. A company with a lower ratio, on the other hand, is usually an indication of poor current and future performance. This could prove to be a poor investment. Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular repair (EVAR) products, including EVAR stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA Proximal Endograft brand names. It also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.
Latest posts by Eldred Matthew (see all)
- Investors Focused Stock: Sarepta Therapeutics, Inc.’s (SRPT) - February 17, 2017
- Investors Spotlight: Baxter International Inc.’s (BAX) - February 17, 2017
- Investors Reviewing Stock: Clovis Oncology, Inc.’s (CLVS) - February 17, 2017